¼¼°èÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå ±Ô¸ð Á¶»ç, À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global Inhalation Anesthesia Market Size study, by Type (Desflurane, Sevoflurane, Isoflurane, and Other Types), by End-User (Hospital, Ambulatory Surgical Centers, Other End Users), and Regional Forecasts 2022-2032
»óǰÄÚµå
:
1477058
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2024³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 200 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è ÈíÀÔ ¸¶ÃëÁ¦ ½ÃÀåÀº 2023³â ¾à 13¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 4.57% ÀÌ»óÀÇ °ß½ÇÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Èֹ߼º ¸¶ÃëÁ¦·Îµµ ¾Ë·ÁÁø ÈíÀÔ ¸¶ÃëÁ¦´Â Àü½Å ¸¶Ãë ¹× ÁøÁ¤ÀÇ ½ÃÀÛ°ú À¯Áö¿¡ ÇʼöÀûÀ̸ç, ȯÀÚÀÇ ¾ÈÀü°ú ½Ã¼úÀÇ È¿À²¼º¿¡ ´ëÇÑ Á߿伺ÀÌ °Á¶µÇ°í ÀÖ½À´Ï´Ù. ÁÖ·Î ÈíÀÔÀ» ÅëÇØ Åõ¿©µÇ¸ç, Á¤¸ÆÀ̳ª ´Ù¸¥ °æ·Î¿¡ ºñÇØ ½Ç¿ëÀûÀÎ ÀåÁ¡ÀÌ ÀÖ¾î ¸¶Ãë ¼öÁØÀ» Á¤È®ÇÏ°Ô Á¦¾îÇÏ°í ½Å¼ÓÇÏ°Ô Á¶ÀýÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç ÁÖ¿ä ÈíÀÔ ¸¶ÃëÁ¦¿¡´Â µ¥½ºÇ÷ç¶õ, ¼¼º¸Ç÷ç¶õ, ¾Æ»êÈÁú¼Ò µîÀÌ ÀÖÀ¸¸ç, ¼ö¼ú·® Áõ°¡¿Í ¸¶Ãë µµÀÔ ½Ã½ºÅÛÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ¸¶ÃëÁ¦ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¼¼º¸Ç÷ç¶õÀÇ ºü¸¥ ÀÛ¿ë ¹ßÇö°ú ȸº¹ ½Ã°£Àº ȸº¹ ±â°£ ´ÜÃà°ú ȯÀÚ °á°ú °³¼±¿¡ ´ëÇÑ ¿ä±¸¿Í ÀÏÄ¡ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â º¸´Ù ¾ÈÀüÇϰí È¿À²ÀûÀÎ ¸¶Ãë ÇÁ·ÎÅäÄÝ·ÎÀÇ ÀüȯÀ» °Á¶Çϰí Çö´ë ¸¶Ãë Áø·áÀÇ »óȲÀ» Çü¼ºÇϰí ÈíÀÔ ¸¶Ãë ±â¼úÀÇ Çõ½ÅÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
°í·ÉÈ »çȸ¿Í ÀÇ·á ¼ºñ½º Á¢±Ù¼º È®´ë¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î ¿Ü°ú ¼ö¼úÀÌ Áõ°¡ÇÏ¸é¼ ÈíÀÔ ¸¶ÃëÁ¦ ½ÃÀåÀÌ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿Ü°ú ¼ö¼úÀÇ ±ÞÁõÀº ¼±ÅÃÀûÀÌµç ºñ¼±ÅÃÀûÀ̵ç Çö´ë ¸¶Ãë Áø·áÀÇ ±âº» ±¸¼º ¿ä¼ÒÀÎ ÈíÀÔ ¸¶ÃëÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½º¸¶Æ® ¸ð´ÏÅ͸µ ÀåÄ¡, Æó¼â ·çÇÁ ¸¶Ãë ½Ã½ºÅÛ µî ¸¶Ãë Àü´Þ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀüÀ¸·Î ¸¶Ãë Åõ¿©ÀÇ ¾ÈÀü¼º°ú Á¤È®¼ºÀÌ Çâ»óµÇ¸é¼ ¸¶ÃëÁ¦ ½ÃÀå ¼ºÀå¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Àå½Ã°£ ¸¶Ãë ³ëÃâ·Î ÀÎÇÑ ÀáÀçÀû ºÎÀÛ¿ë, ÀǾàǰ ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ÀÇ·á ½Ã½ºÅÛ ³» °¡°Ý ¾Ð¹Ú µîÀÇ ¹®Á¦µµ ¿©ÀüÈ÷ ³²¾Æ ÀÖ½À´Ï´Ù. ±×·¯³ª ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸ °³¹ßÀº À§ÇèÀ» ÁÙÀ̰í ÈíÀÔ ¸¶ÃëÁ¦ÀÇ ¾ÈÀü¼º°ú À¯È¿¼º ÇÁ·ÎÆÄÀÏÀ» °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ¾î 2022³âºÎÅÍ 2032³â±îÁö ÈíÀÔ ¸¶ÃëÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ¾ïÁ¦ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¼¼°è ÈíÀÔ ¸¶ÃëÁ¦ ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ ¼¼°è Áö¿ªÀ¸·Î, 2023³â ºÏ¹Ì°¡ ÈíÀÔ ¸¶ÃëÁ¦ ½ÃÀå¿¡¼ ½ÃÀå Á¡À¯À²À» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â Çõ½ÅÀûÀÎ ÈíÀÔ ¸¶ÃëÁ¦ ¿¬±¸ °³¹ß¿¡ ´ëÇÑ Á¤ºÎ ÅõÀÚ Áõ°¡¿Í ÀÌ Áö¿ªÀÇ ¾Ï ¹ß»ý·ü Áõ°¡·Î ÀÎÇØ ÃËÁøµÉ °ÍÀÔ´Ï´Ù. Áúº´ È®»ê°ú Áúº´ °ü¸®¸¦ À§ÇÑ ¿Ü°úÀû °³ÀÔÀÇ Çʿ伺Àº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Ãß°¡ ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ij³ª´Ù Á¤ºÎÀÇ Åë°è¿¡ µû¸£¸é Æó¾Ï, À¯¹æ¾Ï, ´ëÀå¾Ï, Àü¸³¼±¾Ï µî ¾Ï Áø´Ü ¹× »ç¸Á·ü¿¡ ´ëÇÑ ¿ì·Á½º·¯¿î ¿¹ÃøÀÌ ¹ßÇ¥µÇ¾ú½À´Ï´Ù. ¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÃÖ¼Ò Ä§½À ¼ö¼ú ¹× °³º¹ ¼ö¼úÀ» Æ÷ÇÔÇÑ ¿Ü°úÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ÈíÀÔ ¸¶ÃëÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÇ ¼ö·ÅÀº ºÏ¹Ì°¡ ÈíÀÔ ¸¶ÃëÁ¦ ½ÃÀåÀÇ ±Ëµµ¸¦ Çü¼ºÇÏ´Â µ¥ ÀÖ¾î ºÏ¹Ì°¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ´Ù´Â °ÍÀ» µÞ¹ÞħÇÕ´Ï´Ù.
ÀÌ º¸°í¼¿¡ Æ÷ÇÔµÈ ÁÖ¿ä ½ÃÀå ±â¾÷
- Merck KGaA
- AbbVie Inc.
- Baxter International Inc.
- Fresenius Kabi AG (Fresenius SE& Co. KGaA
- Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC)
- Hikma Pharmaceuticals PLC
- Jiangsu Hengrui Medicine Co. Ltd
- Lunan Pharmaceutical Group Co. Ltd
- Piramal Enterprises Limited
- Troikaa Pharmaceuticals Ltd
¸ñÂ÷
Á¦1Àå ¼¼°èÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå Á¤ÀÇ¿Í Á¶»çÀÇ ÀüÁ¦Á¶°Ç
- Á¶»ç ¸ñÀû
- ½ÃÀåÀÇ Á¤ÀÇ
- Á¶»çÀÇ ÀüÁ¦Á¶°Ç
- Æ÷ÇÔ°ú Á¦¿Ü
- Á¦ÇÑ »çÇ×
- °ø±ÞÃø ºÐ¼®
- °¡¿ë¼º
- ÀÎÇÁ¶ó
- ±ÔÁ¦ ȯ°æ
- ½ÃÀå °æÀï
- °æÁ¦¼º(¼ÒºñÀÚ ½ÃÁ¡)
- ¼ö¿äÃø ºÐ¼®
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ±â¼ú Áøº¸
- ģȯ°æ
- ¼ÒºñÀÚ Àǽİú ¼ö¿ë
- Á¶»ç ¹æ¹ý
- Á¶»ç ´ë»ó³âµµ
- ÅëÈ È¯»êÀ²
Á¦2Àå ÁÖ¿ä ¿ä¾à
- ¼¼°èÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå ±Ô¸ð£¦¿¹Ãø(2022³â-2032³â)
- Áö¿ªº° °³¿ä
- ºÎ¹®º° °³¿ä
- ÁÖ¿ä µ¿Çâ
- °æ±âÈÄÅðÀÇ ¿µÇâ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦3Àå ¼¼°èÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ½ÃÀå ±âȸ
Á¦4Àå ¼¼°èÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ¹ÙÀ̾îÀÇ ±³¼··Â
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷°£ °æÀï °ü°è
- Porter's Five Forces ¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PESTEL ºÐ¼®
- Á¤Ä¡
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦5Àå ¼¼°èÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå ±Ô¸ð¡¤À¯Çüº° ¿¹Ãø : 2022³â-2032³â
- Desflurane
- Sevoflurane
- Isoflurane
- ±âŸ À¯Çü
Á¦6Àå ¼¼°èÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2022³â-2032³â
- º´¿ø
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- ±âŸ ÃÖÁ¾»ç¿ëÀÚ
Á¦7Àå ¼¼°èÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå ¼¼°èÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå ±Ô¸ð, Áö¿ªº° ¿¹Ãø, 2022³â-2032³â
- ºÏ¹ÌÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ¹Ì±¹
- À¯Çüº° ½ÃÀå ±Ô¸ð£¦¿¹Ãø, 2022³â-2032³â
- ÃÖÁ¾»ç¿ëÀÚ ³»¿ª »çÀÌÁ¿¹Ãø, 2022³â-2032³â
- ij³ª´Ù ÈíÀÔ ¸¶Ãë ½ÃÀå
- À¯·´ÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ¿µ±¹ÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- µ¶ÀÏÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ÇÁ¶û½ºÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ½ºÆäÀÎÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ÀÌÅ»¸®¾ÆÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ±âŸ À¯·´ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- Áß±¹ÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ÀεµÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ÀϺ»ÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- È£ÁÖÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- Çѱ¹ÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç ÈíÀÔ ¸¶Ãë ½ÃÀå
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ºê¶óÁúÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ¸ß½ÃÄÚÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« ÈíÀÔ ¸¶Ãë ½ÃÀå
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- »ç¿ìµð¾Æ¶óºñ¾ÆÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹ÀÇ ÈíÀÔ ¸¶Ãë ½ÃÀå
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÈíÀÔ ¸¶Ãë ½ÃÀå
Á¦8Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- Merck KGaA
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
- Á¦Ç° °³¿ä
- ½ÃÀå Àü·«
- AbbVie Inc.
- Baxter International Inc.
- Fresenius Kabi AG(Fresenius SE& Co. KGaA)
- Dechra Pharmaceuticals PLC(Halocarbon Life Sciences LLC)
- Hikma Pharmaceuticals PLC
- Jiangsu Hengrui Medicine Co. Ltd
- Lunan Pharmaceutical Group Co. Ltd
- Piramal Enterprises Limited
- Troikaa Pharmaceuticals Ltd
Á¦9Àå Á¶»ç °úÁ¤
- Á¶»ç °úÁ¤
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
LSH
¿µ¹® ¸ñÂ÷
Global Inhalation Anesthesia Market is valued at approximately USD 1.3 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.57% over the forecast period 2024-2032. Inhalational anesthetics, also known as volatile anesthetic agents, are essential in initiating and maintaining general anesthesia and sedation, with a growing emphasis on patient safety and procedural efficiency. Administered primarily via inhalation due to practical advantages over intravenous and alternative routes, they ensure precise control and rapid adjustment of anesthesia levels. Key inhalational anesthetics in current practice include desflurane, sevoflurane, and nitrous oxide, driven by increasing surgical volumes and advancements in anesthesia delivery systems. Particularly, sevoflurane's rapid onset of action and recovery time align with the demand for shorter recovery periods and enhanced patient outcomes. This trend underscores a shift towards safer and more efficient anesthesia protocols, shaping the landscape of modern anesthesia practice and driving innovation in inhalational anesthetic technologies.
The rise in surgical procedures globally is propelling the Inhalation Anesthetics Market, driven by an aging population, and expanded healthcare access. This surge in surgeries, both elective and non-elective, underscores the persistent demand for inhalational anesthetics as a fundamental component of modern anesthesia practice. Additionally, technological advancements in anesthesia delivery systems, such as smart monitoring devices and closed-loop anesthesia systems, are enhancing safety and precision in anesthesia administration, further boosting the market growth. However, challenges persist, including potential adverse effects of prolonged anesthesia exposure, stringent regulatory requirements for drug approval, and pricing pressures within healthcare systems. However, ongoing research and development efforts aim to mitigate risks and improve the safety and efficacy profile of inhalational anesthetics, on the other hand, will stifle Inhalation Anesthesia market growth between 2022 and 2032.
The key regions considered for the global Inhalation Anesthesia Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America leading the market share of the Inhalation Anesthesia Market. This dominance is fueled by increased government investment in research and development of innovative inhalation anesthetics, coupled with a rising incidence of cancer in the region. The prevalence of diseases and the necessity for surgical interventions for disease management are additional factors propelling market growth. For instance, statistics from the Government of Canada reveal alarming projections of cancer diagnoses and mortality rates, with lung, breast, colorectal, and prostate cancers being the most prevalent. As cancer incidence rises, the demand for surgical treatments, including minimally invasive and open surgeries, intensifies, thereby driving the demand for inhalation anesthetics. This convergence of factors underscores North America's pivotal role in shaping the trajectory of the Inhalation Anesthesia Market.
Major market player included in this report are:
- Merck KGaA
- AbbVie Inc.
- Baxter International Inc.
- Fresenius Kabi AG (Fresenius SE& Co. KGaA
- Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC)
- Hikma Pharmaceuticals PLC
- Jiangsu Hengrui Medicine Co. Ltd
- Lunan Pharmaceutical Group Co. Ltd
- Piramal Enterprises Limited
- Troikaa Pharmaceuticals Ltd
The detailed segments and sub-segment of the market are explained below:
By Type
- Desflurane
- Sevoflurane
- Isoflurane
- Other Types
By End-user
- Hospital
- Ambulatory Surgical Centers
- Other End Users
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1.Global Inhalation Anesthesia Market Definition and Research Assumptions
- 1.1.Research Objective
- 1.2.Market Definition
- 1.3.Research Assumptions
- 1.3.1.Inclusion & Exclusion
- 1.3.2.Limitations
- 1.3.3.Supply Side Analysis
- 1.3.3.1.Availability
- 1.3.3.2.Infrastructure
- 1.3.3.3.Regulatory Environment
- 1.3.3.4.Market Competition
- 1.3.3.5.Economic Viability (Consumer's Perspective)
- 1.3.4.Demand Side Analysis
- 1.3.4.1.Regulatory frameworks
- 1.3.4.2.Technological Advancements
- 1.3.4.3.Environmental Considerations
- 1.3.4.4.Consumer Awareness & Acceptance
- 1.4.Estimation Methodology
- 1.5.Years Considered for the Study
- 1.6.Currency Conversion Rates
Chapter 2.Executive Summary
- 2.1.Global Inhalation Anesthesia Market Size & Forecast (2022- 2032)
- 2.2.Regional Summary
- 2.3.Segmental Summary
- 2.3.1.By Type
- 2.3.2.By End-user
- 2.4.Key Trends
- 2.5.Recession Impact
- 2.6.Analyst Recommendation & Conclusion
Chapter 3.Global Inhalation Anesthesia Market Dynamics
- 3.1.Market Drivers
- 3.2.Market Challenges
- 3.3.Market Opportunities
Chapter 4.Global Inhalation Anesthesia Market Industry Analysis
- 4.1.Porter's 5 Force Model
- 4.1.1.Bargaining Power of Suppliers
- 4.1.2.Bargaining Power of Buyers
- 4.1.3.Threat of New Entrants
- 4.1.4.Threat of Substitutes
- 4.1.5.Competitive Rivalry
- 4.1.6.Futuristic Approach to Porter's 5 Force Model
- 4.1.7.Porter's 5 Force Impact Analysis
- 4.2.PESTEL Analysis
- 4.2.1.Political
- 4.2.2.Economical
- 4.2.3.Social
- 4.2.4.Technological
- 4.2.5.Environmental
- 4.2.6.Legal
- 4.3.Top investment opportunity
- 4.4.Top winning strategies
- 4.5.Disruptive Trends
- 4.6.Industry Expert Perspective
- 4.7.Analyst Recommendation & Conclusion
Chapter 5.Global Inhalation Anesthesia Market Size & Forecasts by Type 2022-2032
- 5.1.Desflurane
- 5.2.Sevoflurane
- 5.3.Isoflurane
- 5.4.Other Types
Chapter 6.Global Inhalation Anesthesia Market Size & Forecasts by End-user 2022-2032
- 6.1.Hospital
- 6.2.Ambulatory Surgical Centers
- 6.3.Other End Users
Chapter 7.Global Inhalation Anesthesia Market Size & Forecasts by Region 2022-2032
- 7.1.North America Inhalation Anesthesia Market
- 7.1.1.U.S. Inhalation Anesthesia Market
- 7.1.1.1. Type breakdown size & forecasts, 2022-2032
- 7.1.1.2.End-user breakdown size & forecasts, 2022-2032
- 7.1.2.Canada Inhalation Anesthesia Market
- 7.2.Europe Inhalation Anesthesia Market
- 7.2.1.U.K. Inhalation Anesthesia Market
- 7.2.2.Germany Inhalation Anesthesia Market
- 7.2.3.France Inhalation Anesthesia Market
- 7.2.4.Spain Inhalation Anesthesia Market
- 7.2.5.Italy Inhalation Anesthesia Market
- 7.2.6.Rest of Europe Inhalation Anesthesia Market
- 7.3.Asia-Pacific Inhalation Anesthesia Market
- 7.3.1.China Inhalation Anesthesia Market
- 7.3.2.India Inhalation Anesthesia Market
- 7.3.3.Japan Inhalation Anesthesia Market
- 7.3.4.Australia Inhalation Anesthesia Market
- 7.3.5.South Korea Inhalation Anesthesia Market
- 7.3.6.Rest of Asia Pacific Inhalation Anesthesia Market
- 7.4.Latin America Inhalation Anesthesia Market
- 7.4.1.Brazil Inhalation Anesthesia Market
- 7.4.2.Mexico Inhalation Anesthesia Market
- 7.4.3.Rest of Latin America Inhalation Anesthesia Market
- 7.5.Middle East & Africa Inhalation Anesthesia Market
- 7.5.1. Saudi Arabia Inhalation Anesthesia Market
- 7.5.2. South Africa Inhalation Anesthesia Market
- 7.5.3.Rest of Middle East & Africa Inhalation Anesthesia Market
Chapter 8.Competitive Intelligence
- 8.1.Key Company SWOT Analysis
- 8.2.Top Market Strategies
- 8.3.Company Profiles
- 8.3.1. Merck KGaA
- 8.3.1.1.Key Information
- 8.3.1.2.Overview
- 8.3.1.3.Financial (Subject to Data Availability)
- 8.3.1.4.Product Summary
- 8.3.1.5.Market Strategies
- 8.3.2. AbbVie Inc.
- 8.3.3.Baxter International Inc.
- 8.3.4.Fresenius Kabi AG (Fresenius SE& Co. KGaA
- 8.3.5.Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC)
- 8.3.6.Hikma Pharmaceuticals PLC
- 8.3.7.Jiangsu Hengrui Medicine Co. Ltd
- 8.3.8.Lunan Pharmaceutical Group Co. Ltd
- 8.3.9.Piramal Enterprises Limited
- 8.3.10.Troikaa Pharmaceuticals Ltd
Chapter 9.Research Process
- 9.1.Research Process
- 9.1.1.Data Mining
- 9.1.2.Analysis
- 9.1.3.Market Estimation
- 9.1.4.Validation
- 9.1.5.Publishing
- 9.2.Research Attributes
°ü·ÃÀÚ·á